These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 8795592)
21. Immunologic therapy of multiple sclerosis. Arnason BG Annu Rev Med; 1999; 50():291-302. PubMed ID: 10073279 [TBL] [Abstract][Full Text] [Related]
22. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis]. Gusev EI; Boĭko AN; Pozer Ch Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395 [No Abstract] [Full Text] [Related]
23. Disease modifying treatment in multiple sclerosis. Fuller GN; Bone I J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780 [No Abstract] [Full Text] [Related]
24. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
26. How should we proceed with disease-modifying treatments for multiple sclerosis? Andersson PB; Waubant E; Goodkin DE Lancet; 1997 Mar; 349(9052):586-7. PubMed ID: 9057726 [No Abstract] [Full Text] [Related]
28. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature. Mahurkar S; Suppiah V; O'Doherty C Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284 [TBL] [Abstract][Full Text] [Related]
29. NICE and drugs for multiple sclerosis. National Institute of Clinical Excellence. Hartung HP Lancet; 2000 Sep; 356(9235):1114. PubMed ID: 11009171 [No Abstract] [Full Text] [Related]
30. Disease modifying therapies in multiple sclerosis: could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate? Rotondi M; Bergamaschi R; Chiovato L Mult Scler; 2014 Dec; 20(14):1918-9. PubMed ID: 24812044 [No Abstract] [Full Text] [Related]
34. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis. Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877 [TBL] [Abstract][Full Text] [Related]
35. Newer versus older treatments for relapsing-remitting multiple sclerosis. Weinstock-Guttman B; Cohen JA Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526 [TBL] [Abstract][Full Text] [Related]
36. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935 [TBL] [Abstract][Full Text] [Related]
37. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Richert ND Neurology; 2002 May; 58(9):1440-1; author reply 1441-2. PubMed ID: 12011306 [No Abstract] [Full Text] [Related]
38. Comparative studies of glatiramer acetate and interferon beta. Goodin D Int MS J; 2008 Jun; 15(2):39-41. PubMed ID: 18782497 [TBL] [Abstract][Full Text] [Related]
39. [Beta-interferon and multiple sclerosis]. Clanet M Rev Neurol (Paris); 1993; 149(8-9):443-4. PubMed ID: 8009140 [No Abstract] [Full Text] [Related]
40. Comparative efficacy of interferon β versus glatiramer acetate for relapsing-remitting multiple sclerosis. La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1016-20. PubMed ID: 25550414 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]